This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is a Beat in the Offing for Humana's (HUM) Q1 Earnings?
by Zacks Equity Research
Humana's (HUM) Q1 earnings are likely to gain on higher membership and a solid Medicare Advantage.
Adverum Biotechnologies (ADVM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Adverum Biotechnologies (ADVM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
What Bargains? Play 5 Stocks With Rising P/E Instead
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Adverum Biotechnologies (ADVM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Adverum Biotechnologies (ADVM) delivered earnings and revenue surprises of 13.33% and 205.13%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Adverum Biotechnologies (ADVM) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Adverum Biotechnologies (ADVM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Adverum Biotechnologies (ADVM) is a Top Pick for Momentum Investors
by Zacks Equity Research
Does Adverum Biotechnologies (ADVM) have what it takes to be a top stock pick for momentum investors? Let's find out.
Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank
by Zacks Equity Research
Zacks.com highlights: American Woodmark, Adverum Biotechnologies, Merrimack Pharmaceuticals, Athene Holding and M&T Bank
Move Beyond Bargain Hunting: 5 Stocks With Rising P/E
by Sanghamitra Saha
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
Can The Uptrend Continue for Adverum Biotechnologies (ADVM)?
by Zacks Equity Research
Investors certainly have to be happy with Adverum Biotechnologies, Inc. (ADVM) and its short term performance.
What's in Store for Adverum (ADVM) This Earnings Season?
by Zacks Equity Research
On Adverum's (ADVM) second-quarter 2018 conference call, investor focus will be on the company's progress with its pipeline candidates.
5 Biotech Stocks Set to Beat Estimates This Earnings Season
by Zacks Equity Research
Given the large number of biotech firms, the task of selecting stocks with possibilities to beat estimates could appear daunting. We pick five biotech stocks likely to deliver an earnings surprise.
Is a Beat in Store for Epizyme (EPZM) This Earnings Season?
by Zacks Equity Research
Epizyme (EPZM) is expected to provide updates on pipeline candidates when it reports Q1 results on May 8.
Puma Biotech (PBYI) to Report Q1 Earnings: What to Expect?
by Zacks Equity Research
On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.
What's in Store for Horizon Pharma (HZNP) in Q1 Earnings?
by Zacks Equity Research
On Horizon Pharma's (HZNP) first-quarter 2018 earnings call, investors focus will be on the performance of its business units and key products.
The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum
by Zacks Equity Research
The Zacks Analyst Blog Highlights: UnitedHealth, Envision, Addus and Adverum
3 Healthcare Stocks Set to Beat Q1 Earnings Estimates
by Zacks Equity Research
Elevated flu activity, aging population, high expenses, and a low tax rate would influence healthcare stocks' earnings in Q1.
What's in the Cards for Inovio (INO) This Earnings Season?
by Zacks Equity Research
Inovio's (INO) most advanced pipeline candidate, VGX-3100's progress remains in focus. However, lack of an approved product in the company's portfolio is a dampener.
Envision Healthcare (EVHC) to Report Q1 Earnings: What's Up?
by Zacks Equity Research
Envision Healthcare's (EVHC) Q1 earnings should see an upside from higher revenues at both its segments.
What's in the Cards for Merrimack (MACK) in Q1 Earnings?
by Zacks Equity Research
Investor focus is likely to remain on Merrimack's (MACK) pipeline updates when it reports first-quarter numbers.
What Lies Ahead for Ligand (LGND) This Earnings Season? (Revised)
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.
What's in the Cards for Aerie (AERI) This Earnings Season?
by Zacks Equity Research
Investors are expected to focus on Rhopressa's launch and other pipeline updates when it reports results for the first-quarter (scheduled on May 8).
What Lies Ahead for Ligand (LGND) This Earnings Season?
by Zacks Equity Research
Ligand's (LGND) Captisol formulation technology propels the company to pair up with several leading healthcare companies, which in turn might drive the stock in Q1.
Is a Beat in the Cards for Perrigo (PRGO) in Q1 Earnings?
by Zacks Equity Research
Perrigo's (PRGO) product purchases and introductions in the Rx segment might shoot up sales in the near future.
Jazz Pharmaceuticals (JAZZ) Q1 Earnings: What's in Store?
by Zacks Equity Research
Investor focus is likely to be on Xyrem's performance, the lead product of Jazz Pharmaceuticals (JAZZ) for excessive daytime sleepiness. Also, the company's pipeline progress might grab attention.
What's in Store for Intrexon (XON) This Earnings Season?
by Zacks Equity Research
Intrexon Corporation (XON) is expected to report first-quarter 2018 results on May 9, after the market closes, and will provide developmental updates during the quarterly call.